Can a patient miss a dose of Spravato (esketamine) during the induction phase and still complete the induction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Missing a Spravato Dose During Induction Phase

Yes, a patient can miss a dose of Spravato during the induction phase and still complete induction, provided there is no worsening of depressive symptoms—simply continue with the current twice-weekly dosing schedule. 1

FDA-Approved Guidance on Missed Doses

The FDA label explicitly addresses this scenario with clear instructions: "If a patient misses treatment session(s), provided there is no worsening of their depressive symptoms, the patient should continue the current dosing schedule." 1 This guidance applies to both induction and maintenance phases, though the label specifically notes that dose schedule adjustments (reverting to more frequent dosing) are primarily relevant during maintenance treatment when depression symptoms worsen. 1

Induction Phase Structure

The standard induction phase consists of:

  • Twice-weekly dosing for 4 weeks (56 mg or 84 mg per session)
  • Target of 8 total treatment sessions
  • Therapeutic benefit should be evaluated at the end of induction to determine continuation 1

Real-World Implementation Considerations

Important caveat: Real-world data reveals that patients typically require significantly more time than the label-recommended 28 days to complete induction. A 2024 study found the mean time to complete 8 esketamine sessions was 73.2 days (versus the expected 28 days), with 75.2% of patients going on to complete maintenance treatment. 2 This suggests clinical flexibility in timing is both common and acceptable in practice.

Clinical Decision Algorithm for Missed Doses

If dose(s) missed during induction:

  1. Assess depression status:

    • No worsening → Continue twice-weekly schedule, extend induction timeline as needed
    • Worsening symptoms → Evaluate whether to continue esketamine or consider alternative interventions
  2. Monitor for therapeutic benefit at completion:

    • The critical endpoint is completing adequate treatment sessions (typically 8), not rigid adherence to a 4-week timeline
    • Evidence of benefit should be assessed before transitioning to maintenance 1

Safety and Efficacy Context

Long-term studies demonstrate that patients who complete induction (even with extended timelines) show sustained improvement, with mean MADRS score reductions of -16.4 points maintained through maintenance phases. 3, 4 The key is achieving adequate exposure to treatment sessions rather than strict calendar adherence.

Bottom line: Missing doses during induction does not disqualify completion of the phase—the focus should be on achieving the target number of treatment sessions while monitoring clinical response, not rigid calendar compliance.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.